6533b855fe1ef96bd12b1340

RESEARCH PRODUCT

Determination of furosemide in urine samples by direct injection in a micellar liquid chromatographic system.

María-josé Ruíz-angelSamuel Carda-brochM.c. García-alvarez-coqueJosep Esteve-romero

subject

Detection limitChromatographyMetabolitemedicine.medical_treatmentSodiumchemistry.chemical_elementFurosemideReversed-phase chromatographyUrineBiochemistryAnalytical Chemistrychemistry.chemical_compoundchemistryFurosemideElectrochemistrymedicineEnvironmental ChemistryHumansDiureticDiureticsQuantitative analysis (chemistry)SpectroscopyChromatography High Pressure Liquidmedicine.drugChromatography Micellar Electrokinetic Capillary

description

A sensitive, selective and efficient micellar liquid chromatographic (MLC) procedure was developed for the determination of furosemide (4-chloro-N-furfuryl-5-sulfamoylanthranilic acid) in urine samples by direct injection and UV detection. The procedure makes use of a C18 reversed-phase column and a micellar mobile phase of 0.05 mol l(-1) sodium dodecyl sulfate-6% v/v propanol and phosphate buffer at pH 3 to resolve furosemide from its photochemical degradation products. The importance of protecting the standards and urine samples to be analysed from light in the assay of furosemide, avoiding its degradation, was verified. The limit of quantification was 0.15 microg ml(-1) and the relative standard deviation of the inter-day assay was 0.8-0.04% in the 6-82 microg ml(-1) range. Detection of urinary excretion of furosemide was followed up to 12 h after ingestion of the drug by a healthy volunteer. No potential interference from the major metabolite (furosemide acylglucuronide) and its hydrolytic product (4-chloro-5-sulfamoylanthranilic acid) was observed. Commonly administered drugs also did not interfere. The proposed MLC procedure permits the rapid and reproducible measurement of low levels of furosemide in a small amount of urine.

10.1039/b108358ahttps://pubmed.ncbi.nlm.nih.gov/11827392